Southern Fox Investments Limited investment portfolio

Argonaute RNA Ltd develops RNA‑interference therapeutics by applying a proprietary modification that stabilises small‑interfering RNA (siRNA) to enable safe, short‑duration gene silencing. Its platform targets disease areas such as cardiometabolic disorders, offering bispecific and dual‑siRNA molecules for therapeutic use.

CBDerma Technology Limited develops cannabinoid‑based pharmaceutical products, using transdermal delivery technology (DermaSys) to create topical cannabidiol formulations for the medical market. It collaborates with partners such as Futura Medical to advance these therapies.